B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 92.1%

Neg 92.1% Neu 0% Pos 0%

B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ:AMPH) from Neutral to Underperform and lowers the price target from $25 to $20.